Bundling devices

Use without innovation (i.e. vaccine and diluent in separate packaging)

Section 1: Summary of innovation

1.1 Examples of innovation types:

GSK's vial clip (1,2)

The bundling vial clip can be used between identical sized vials.

Bundling clip:



Bundling clip connecting two vials:



Use of bundling clip for vials in a secondary package:



Vaccine vial and diluent ampoule packaging combination (1)

As vials and ampoules have different diameters and heights, it is challenging to use the bundling clip to package them together. One approach is to use a moulded tray to package the different formats of the primary containers together.



Vaccine vial, diluent and syringe combination^a



Vaccine vial and diluent packaging combination (1)


Individual cartons can also be used as a secondary packaging strategy to bundle a pair of vials (vaccine and diluent) together.



12.06.2019 Page 1 of 18

^a https://cdn.vaccineingredients.net/wp-content/uploads/2017/03/hib-hiberix.jpg

Category: Packaging and safety
Innovation: Bundling devices





1.2. Description of innovation:

- Bundling devices allow vaccine components to be physically connected or placed together in the same secondary packaging to reduce the possibility of their separation and improve the likelihood of correct preparation and administration.
- Vaccine manufacturers adopt different packaging strategies to couple or bundle their vaccine products with diluents/buffers and/or reconstituting equipment as shown in table 1.
- There are multiple combinations in which the vaccine, diluent and / or devices can be bundled, some examples of combinations of vaccine primary packaging and devices include:
 - Vaccine vial and diluent vial:
 - Vaccine vial and diluent ampoule;
 - Vaccine ampoule and diluent ampoule;
 - Vaccine vial and sachet;
 - Vaccine vial, diluent vial, vial adapter, and reconstitution syringe;
 - Vaccine vial and prefilled syringe containing diluent;
 - Vaccine vial and dropper.

1.3 Examples of innovations and developers:

Table 1.

| Product name; Image | Developer (place); website | Brief description, notes |
|--|--|---|
| Image source: b | GlaxoSmithKline (GSK) has been using the bundling clips with some of their vaccines. | Bundling clips are used or have been used with GlaxoSmithKline's (GSK) Tritanrix [™] HB+Hib pentavalent vaccine (WHO prequalified in October 2003 but currently discontinued) and their new Mosquirix [™] malaria vaccine. (2). |
| IMDJEV. | Imojev | 1 vial (vaccine powder) + 1 |
| The control of March for appearant for appearant for the control of the control o | Live attenuated Japanese encephalitis vaccine | vial (diluent) + 1 syringe + 2 separate needles stored together in a preformed |
| | Sanofi Hong Kong Ltd | tray. |
| Image source: c | | |

^b http://www.dewereldmorgen.be/images/cache/xl/2016/11/21/mosquirix.jpg

12.06.2019 Page 2 of 18

[°] http://www.hkapi.hk/images/drugs_images/Imojev%2001.jpg

Category: Packaging and safety Innovation: Bundling devices



Use without innovation (i.e. vaccine and diluent in separate packaging) Comparator:


| Product name; Image | Developer (place); website | Brief description, notes |
|--|---|--|
| Haemophilus b Conjugate Vaccine Internot Gorigopate Acthilis* SANOFI PASTEUR SANO | ACTHIB Vaccine Sanofi Pasteur https://allmedtech.com/acvabsiviwid.html | 5 single-dose vials with diluent for reconstitution packaged together in a secondary carton. |
| Hiberix Hiberix Personal advance for the court of the c | Hiberix [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] GlaxoSmithKline Biologicals | Preformed tray containing lyophilised vaccine, diluent and syringe |
| Image source: f | MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Novartis | Meningitis A lyophilized conjugate vaccine component in a vial and the Meningitis CYW-135 liquid conjugate vaccine component in a prefilled syringe. Both are packaged together with needles for reconstitution and delivery in a preformed tray and secondary carton. |

12.06.2019 Page 3 of 18

d https://cdn.vaccineingredients.net/wp-content/uploads/2017/03/hib-acthib-550x381.gif http://drugline.org/img/drug/11140_11222_1.jpg https://vaccineingredients.net/wp-content/uploads/2017/03/meningococcal-menacwy-menveo.jpg

⁹ https://vaccineingredients.net/vaccines/meningococcal-menacwy-menveo

Category: Packaging and safety
Innovation: Bundling devices





SECTION 2: Summary of assessment for prioritisation

2.1 Key benefits:

- Reduces errors in vaccine preparation, for example using an incorrect diluent to reconstitute a dry vaccine which can result in serious adverse events following immunization (AEFIs). The risks of incorrect diluent use could be greatly reduced if the vaccine and diluent were provided together, e.g. through the use of vial clips (1).
- Reduces mismatching and/or misallocation of vaccine components during distribution potentially reducing vaccine wastage and simplifies inventory processes (1).
- Helps ensure the availability of all the necessary vaccine components for healthcare workers to use for preparing and administering the vaccine, thus potentially reducing missed opportunities (1).
- Breakdowns in the separate supply chains at any level can result in poor stock and vaccine management leading to higher levels of expired vaccine or diluent stock (2). Pairing the vaccine and diluent together during the majority of its journey could eliminate the risk of the health facility storing expired diluents with unexpired vaccines or vice versa (1).

2.2 Key challenges:


- Although bundling vaccine vial and diluent primary containers in the same secondary packaging is
 expected to reduce mismatching errors, if the vials are removed from their secondary packaging the
 risk of incorrect diluent selection returns.
- As vials, ampoules and droppers differ in their dimensions and forms, the bundling of different shaped components together is challenging and would create more bulky packaging compared to the most efficient packaging configuration for each component separately.
- Bundling increases the packaging volume and leads to an increase in the cold chain costs because
 the other bundled components such as the diluent and syringes would be physically attached to the
 vaccine and hence stored and transported in the cold chain, as opposed to being shipped outside of
 the cold chain.

2.3 Additional important information:

- A bundling device or packaging strategy could be lower cost as could be implemented very quickly compared with supplying multi-component vaccines in integrated reconstitution technologies such as dual-chamber vials or dual-chamber prefilled delivery devices.
- As the application of a bundling clip to the vaccine vial and its diluent bears no impact on the aseptic
 filling procedure of the vaccine container, there would be no additional requirement for bridging
 studies to revalidate the containers.
- Since bundling is not currently an established process for all vaccines and vaccine manufacturers, the equipment and packaging process required for this step would need to be purchased, installed, and validated by the vaccine manufacturer.
- Bundling may increase the cost of the vaccine per vial, depending on the approach used. However, for a technology such as a bundling clip connecting two vials, this is expected to be be a minimal fixed cost per clip. With an increased number of doses per vial, the incremental cost of the bundling clip would decline, as the cost would be spread over a larger number of doses. Therefore, bundling multi-dose vials would have less potential impact on the price of vaccine per dose (2).

12.06.2019 Page 4 of 18

Category: Packaging and safety
Innovation: Bundling devices






2.4 Evidence:

- A vaccine packaging study conducted with data from Kenya and Bolivia demonstrated that the
 effect of bundling vaccines significantly increased the volume stored in the cold chain at all levels of
 the supply chain (1).
- A PATH study on the total supply chain impact of bundling (for all vaccine formats, not just lyophilized) found that a 20 percent increase in cold chain capacity would be required if all lyophilized vaccines were bundled with their diluent (2).
- In 1987, AEFIs were reported due to the mistaken reconstitution of measles vaccine with a muscle relaxant compound stored in a vial that looked similar in size and shape to the diluent. Many more cases have been reported across various settings whereby errors made with reconstituting the vaccine with a wrong diluent have resulted in unnecessary deaths and serious AEFIs^h.
- In 2014, a muscle relaxant was mistakenly used to reconstitute a measles vaccine resulting in the death of 15 children in Syria (2).

12.06.2019 Page 5 of 18

h https://www.who.int/vaccine_safety/initiative/detection/managing_AEFIs/en/index4.html

Category: Packaging and safety
Innovation: Bundling devices





SECTION 3: Evaluation criteria

3.1 Health impact criteria

Indicator: Ability of the vaccine presentation to withstand heat exposure

Legend: Green: Better than the comparator: The innovation includes features that may increase heat stability; White: Neutral, no difference with the comparator; Red: Worse than the comparator: The innovation includes features that may decrease heat stability, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.

Table 2.

| Ability of the vaccine presentation to | Parameters to measure against a comparator | Score | Assessment |
|--|--|---------|---|
| withstand heat exposure | Does the innovation have features that may improve heat stability? | Neutral | Bundling devices (or the lack thereof) do not have an impact on the vaccine's heat stability. |

| | No difference to the comparator |
|--|---------------------------------|
|--|---------------------------------|

Indicator: Ability of the vaccine presentation to withstand freeze exposure

Legend: Green: Better than the comparator: The innovation includes features that may increase freeze resistance; White: Neutral, no difference with the comparator; Red: Worse than the comparator: The innovation includes features that may decrease freeze resistance, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.


Table 3.

| Ability of the vaccine presentation to | Parameters to measure against a comparator | Score | Assessment |
|--|---|---------|--|
| withstand freeze exposure | Does the innovation have features that may improve freeze resistance? | Neutral | Bundling devices (or the lack thereof) do not have an impact on the vaccine's freeze resistance. |

| | No difference to the comparator |
|--|---------------------------------|
|--|---------------------------------|

12.06.2019 Page 6 of 18

Category: Packaging and safety
Innovation: Bundling devices





3.2 Coverage and equity criteria

Indicator: Ease of usei

Legend: Dark Green: Considerably better than the comparator: Better for all applicable parameters; Green: Better than the comparator: Better for some of the applicable parameters AND no difference for the rest of the parameters; White: Neutral, no difference with the comparator; Yellow: Mixed: Better than the comparator for some of the applicable parameters AND worse than the comparator for the rest of the parameters; Red: Worse than the comparator: Worse for some of the applicable parameters AND no difference for the rest of the parameters; Dark Red: Considerably worse than the comparator: Worse for all applicable parameters, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.

Table 4.

| • Assessment of the potential for incorrect preparation based on usability data from field studies (or based on design of innovation if field studies not available) • Assessment of the potential for incorrect administration based on usability data from field studies (or based on design of innovation if field studies not available) | Parameters to measure against a comparator | Score | Assessment |
|--|---|---------|--|
| | Does the innovation avoid reconstitution and is that an improvement? | Neutral | Bundling devices do not avoid the need to reconstitute lyophilised vaccines, but bundling physically connects the lyophilized vaccine to the correct diluent to reduce the risk of reconstituting the vaccine with the wrong diluent. Therefore, they reduce the chance for one type of reconstitution error (but not all). This is an improvement over separate packaging and distribution of the vaccine components. |
| | Does the innovation require fewer vaccine product components? | Neutral | Bundling ensures that vaccine components are provided together in a single package or joined with a clip. Because the vaccine is provided in the format, it does not change the number of vaccine product components that are required, or must be assembled, to deliver the vaccine per immunized individual. |
| | Does the innovation require additional components or equipment (such as scanners or label readers)? | Neutral | No additional components are required relative to the comparator. |
| | Does the innovation require fewer preparation steps and less complex preparation steps? | Better | Because all vaccine components are provided in a single package, the preparation is less complex as the health worker does not need to search for separate items in the cold chain and in ambient temperature storage. |

¹ Ease of use can prevent missed opportunities resulting from the complexity of preparation and administration procedures. It could also impact the ability for lesser trained personnel to administer the vaccine (incl. self-administration). It can be assessed based on usability data from field studies (or based on design of innovation if field studies not available).

12.06.2019 Page 7 of 18

¹ This parameter is only assessed for RFID/barcodes, for all other innovations it is not applicable (N/A).

Category: Packaging and safety
Innovation: Bundling devices



Comparator: Use without innovation (i.e. vaccine and diluent in separate packaging)

| Assessment of the potential for incorrect preparation based on usability data from field studies (or based on design of innovation if field studies not available) Assessment of the potential for incorrect administration based on usability data from field studies (or based on design of innovation if field studies not available) | Parameters to measure against a comparator | Score | Assessment |
|---|--|---------|---|
| | Does the innovation improve dose control? | Neutral | The use of bundling has no impact on dose control. |
| | Does the innovation improve targeting the right route of administration? | Neutral | The use of bundling devices has no impact on targeting the right route of administration. |

12.06.2019 Page 8 of 18

Category: Packaging and safety
Innovation: Bundling devices



VIPS VACCINE INNOVATION PRIORITISATION STRATEGY

Comparator: Use without innovation (i.e. vaccine and diluent in separate packaging)

Indicator: Potential to reduce stock outs based on the number of separate components necessary to deliver the vaccine or improved ability to track vaccine commodities

Legend: Green: Better than the comparator for one of the parameters; White: Neutral, no difference with the comparator; Red: Worse than the comparator for one of the parameters, NA: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.


Table 5.

| Potential to reduce stock outs based on the number of separate components necessary to deliver the vaccine or improved ability to track vaccine commodities | Parameters to measure against a comparator | Score | Assessment |
|---|--|---------|---|
| | Does the innovation require fewer components? | Better | As the innovation enables the physical connection of vaccine components in the same primary packaging, this reduces the number of separate vaccine product components to track throughout the supply chain during distribution and storage, thus improving inventory management. This is better and reduces the logistic errors of tracking different components in the supply chain. |
| Assessment of the potential to reduce stock outs based on the innovation's features | Or does the innovation include labelling that facilitates product tracking and is it better than the comparator? | Neutral | Innovations that enable bundling of vaccine components do not impact labelling. |

Better than the comparator

12.06.2019 Page 9 of 18

Category: Packaging and safety
Innovation: Bundling devices





Indicator: Acceptability of the vaccine presentation and schedule to patients/caregivers

Legend: Dark Green: Considerably better than the comparator: Better for all applicable parameters; Green: Better than the comparator: Better for some of the applicable parameters AND no difference for the rest of the parameters; White: Neutral, no difference with the comparator; Yellow: Mixed: Better than the comparator for some of the applicable parameters AND worse than the comparator for the rest of the parameters; Red: Worse than the comparator: Worse for some of the applicable parameters AND no difference for the rest of the parameters; Dark Red: Considerably worse than the comparator: Worse for all applicable parameters, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.


Table 6.

| Acceptability of the vaccine presentation to patients/ caregivers • Does the innovation include features that may improve acceptability of vaccinees and caregivers | Parameters to measure against a comparator | Score | Assessment |
|--|--|---------|--|
| | Painful or not painful | Neutral | Bundling has no impact on administration of the vaccine and perceived pain of administration. |
| | Perception of ease of administration (i.e. convenience for the vaccinees/caregivers) | Neutral | Same as above |
| | Any other tangible benefit to improve/impact acceptability to vaccinees/caregivers | Better | Serious injuries and deaths from vaccine/diluent mismatches are rare, but when they occur they can be widely publicized and shake caregivers' confidence in vaccines and immunization programs. Bundling could reduce these errors and lead to increased acceptability of vaccination. |

Better than the comparator

12.06.2019 Page 10 of 18

Category: Packaging and safety
Innovation: Bundling devices





3.3 Safety criteria

Indicator: Likelihood of contamination

Legend: Dark Green: Considerably better than the comparator: Better for all applicable parameters; Green: Better than the comparator: Better for some of the applicable parameters AND no difference for the rest of the parameters; White Neutral, no difference with the comparator; Yellow: Mixed: Better than the comparator for some of the applicable parameters AND worse than the comparator for the rest of the parameters; Red: Worse than the comparator: Worse for some of the applicable parameters AND no difference for the rest of the parameters; Dark Red: Considerably worse than the comparator: Worse for all applicable parameters, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.


Table 7.

| Likelihood of contamination • Risk assessment of potential for contamination based on design of innovation and on usability data from field studies | Parameters to measure against a comparator | Score | Assessment |
|--|--|---------|--|
| | Does the innovation reduce the risk of contamination while reconstituting the dry vaccine? | Neutral | The use of bundling devices has no impact on the risk of contamination during the process of reconstitution, filling the delivery device and in terms of preparing the vaccine for administration. |
| | Does the innovation reduce the risk of contamination while filling the delivery device? | Neutral | |
| | Does the innovation require fewer preparation steps and less complex preparation steps? | Neutral | |
| | Does the innovation reduce the potential risk of reuse of delivery technology? | Neutral | The common scenario is to have vial/vial bundles for which the risk of re-use and use of sterile components would be no different to the comparator. |
| | Does the innovation reduce the risk of use of nonsterile components? | Neutral | It should be noted that if there is potential to bundle vaccine vials/diluents with delivery device (e.g. oral syringe) or other components (e.g. vial adapters) then the risks would be reduced as each time the vaccine can be delivered with new available delivery devices/components. |

| Neutral No difference to the comparator for vial/vial combination | |
|---|--|
|---|--|

12.06.2019 Page 11 of 18

Category: Packaging and safety
Innovation: Bundling devices





Indicator: Likelihood of needle stick injury

Legend: Dark Green: Considerably better than the comparator: Better for all applicable parameters; Green: Better than the comparator: Better for some of the applicable parameters AND no difference for the rest of the parameters; White: Neutral, no difference with the comparator; Yellow: Mixed: Better than the comparator for some of the applicable parameters AND worse than the comparator for the rest of the parameters; Red: Worse than the comparator: Worse for some of the applicable parameters AND no difference for the rest of the parameters; Dark Red: Considerably worse than the comparator: Worse for all applicable parameters, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.


Table 8.

| Likelihood of needle stick injury • Risk assessment of the | Assessment | | |
|--|---|---------|--|
| presence of sharps during the process of preparing and | Does the innovation contain fewer sharps? | Neutral | Bundling does not impact the vaccine components used or the process of preparing and administering |
| administering the vaccine | Does the innovation use sharps for preparing and/or administering the vaccine and is that better than the comparator? | Neutral | the vaccine. |
| | Does the innovation include an auto disable feature and is that better than the comparator? | Neutral | |
| | If the innovation uses sharps, does it include a sharps injury prevention feature and is that better than the comparator? | Neutral | |
| | Does the innovation reduce the risk of injury after vaccine administration? | Neutral | |

| No difference to the comparator | |
|---------------------------------|--|
|---------------------------------|--|

12.06.2019 Page 12 of 18

Category: Packaging and safety
Innovation: Bundling devices





3.4 Economic costs criteria

Indicator: Total economic cost of storage and transportation of commodities per dosek

Legend: Dark Green: Considerably better than the comparator: Reduces the volume per dose for applicable parameters; Green:

Better than the comparator: Reduces the volume per dose for either of the applicable parameter, and there is no difference for the other; White: Neutral, no difference with the comparator; Yellow: Mixed: Reduces the volume for one of the parameter, and increases the volume for the other parameter compared to the comparator; Red: Worse than the comparator: Increases the volume per dose for either of the applicable parameters, and there is no difference for the other; Dark Red: Considerably worse than the comparator: Increases the volume per dose for both parameters, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.

Table 9.


| Total economic cost of storage and transportation | Parameters to measure against a comparator | Score | Assessment |
|---|---|--------|--|
| of commodities per dose | Does the innovation reduce the volume per dose stored and transported in the cold chain? | Worse | Bundling increases the volume stored in the cold chain as the vaccine is now stored with the diluent and/or devices that are typically not stored in the cold chain (2). |
| | Does the innovation reduce the volume per dose stored /and transported out of the cold chain? | Better | Bundling reduces the volume stored out of the cold chain because the diluent and/or devices are now stored in the cold chain. |

<u>Mixed</u> for the comparator

12.06.2019 Page 13 of 18

^k The assessment of the indicator is volume-related and builds upon PATH's VTIA analysis. A directional estimation is made at this stage, and a better evaluation will be done in Phase II with more antigen-specific data.

Category: Packaging and safety
Innovation: Bundling devices





Indicator: Total economic cost of the time spent by staff per dose

Legend: Dark Green: Considerably better than the comparator: Reduces time for all applicable parameters; Green: Better than the comparator: Reduces time for either, and there is no difference for the other one; White: Neutral, no difference with the comparator; Yellow: Mixed: Reduces the time for one of the parameters, and increases the time for the other parameter; Red: Worse than the comparator: Increases the time for either of the applicable parameters; and there is no difference for the other one; Dark Red: Considerably worse than the comparator: Increases time for all applicable parameters, N/A: the indicator measured is not applicable for the innovation; Grey: no data available to measure the indicator.

Table 10.

| cost of the time | Parameters to measure against a comparator | Score | Assessment |
|------------------|---|---------|---|
| | Does the innovation have attributes that can save time for the vaccinator in preparing and administering the vaccine? | Better | With bundling, the vaccinator saves time that would have been spent matching the vaccine and diluent. |
| | Does the innovation have attributes that save time for staff involved in stock management? | Neutral | There are no attributes of the innovation that would impact the time spent by staff involved in stock management. |

<u>Better</u> than the comparator

12.06.2019 Page 14 of 18

¹ This parameter only applies to barcodes and RFID to capture the benefits for stock management processes, not based on the number of components, but the specific features of the innovation.

Category: Packaging and safety Bundling devices Innovation:



Use without innovation (i.e. vaccine and diluent in separate packaging) Comparator:

Indicator: Total economic cost of one-time/upfront purchases or investments required to introduce the vaccine presentation and of recurrent costs associated with the vaccine presentation (not otherwise accounted for)

Legend: White: Neutral: NO there are no one-time/upfront or recurrent costs and this is not different than the comparator; Red: Worse than the comparator: YES there are one-time/upfront or recurrent costs.


Table 11.

| Total economic cost of one-time/upfront purchases or investments required to | Parameters to measure against a comparator | Score | Assessment |
|--|--|---------|---|
| introduce the vaccine presentation and of recurrent costs associated with the vaccine presentation (not otherwise accounted for) | Are there one-time upfront costs that will be incurred for use of this innovation or recurrent costs that will be incurred for use of this innovation? | Neutral | No. Similar to the comparator, there are no anticipated upfront or recurrent costs for bundling devices. |

| | No difference to the comparator |
|--|---------------------------------|
|--|---------------------------------|

12.06.2019 Page 15 of 18

Category: Packaging and safety
Innovation: Bundling devices





3.5 Secondary criteria on potential breadth of innovation use

Indicator: Applicability of innovation to one or several types of vaccines

Table 12.

Applicability of innovation to one or several types of vaccines

 What vaccines/antigens does the innovation apply to, based on technical feasibility?

Assessment

This innovation could be applied to all vaccines that have more than one component required for preparation and delivery. This innovation can be used for packaging dry vaccines and their diluents to improve safety. Bundling reconstitution and delivery devices is also possible.

MR is an example of a two-component vaccine that could benefit from bundling. ETEC is another potential candidate vaccine.

Indicator: Ability of the technology to facilitate novel vaccine combination Table 13.

Ability of the technology to facilitate novel vaccine combination

 Does the innovation facilitate novel combination vaccine products?


Assessment

No.

Bundling of vaccines is a secondary packaging strategy and has no influence on vaccine formulation.

12.06.2019 Page 16 of 18

Category: Packaging and safety
Innovation: Bundling devices





SECTION 4

4.1 Robustness of data:

Table 14.

| Category | Assessment |
|---|---|
| Type of study | The majority of the data has come from two PATH technical reports (1,3) combined with expert opinion. |
| Inconsistency of results | There are too few comparable studies to assess inconsistency of results. |
| Indirectness of comparison | All the data assessed has been for vaccine applications |
| Indicate the setting in which the study was conducted (low, middle or high income setting); | |
| Comment if the data is on non- vaccine application of the innovation | |

| Overall assessment: | Low to Moderate | |
|---------------------|-----------------|--|
|---------------------|-----------------|--|


4.2 List of technical experts, manufacturers and/or technology developers interviewed for inputs:

Table 15.

| Expert/type | Organisation/contact details | Notes |
|-------------|------------------------------|--------------------------|
| N/A | N/A | No interviews conducted. |

12.06.2019 Page 17 of 18

Category: Packaging and safety
Innovation: Bundling devices





4.3 List of technical experts, manufacturers and/or technology developers that have reviewed and provided feedback/input to the technical notes (TN):

Table 16.

| Reviewers | Organisation/contact details | Notes |
|---|--|-------------------------------|
| Fatema Kazi | GAVI, the Vaccine Alliance fkazi-external-consultant@Gavi.org | Developed and reviewed the TN |
| PATH Medical Devices & Health Technologies Team Debra Kristensen Courtney Jarrahian Mercy Mvundura Collrane Frivold | PATH Debra Kristensen dkristensen@path.org | Reviewed the TN |
| Julian Hickling | Working in Tandem Ltd julian@workingintandem.co.uk | Reviewed the TN |

4.4 References:

- 1. Optimize. Vaccine packaging study Bundling lyophilized vaccines with their diluents and harmonizing their packaging. 2013.
- 2. PATH. Technology Report: Vial Bundling Clip. An overview report on vial bundling clips to prevent reconstitution errors.
- 3. PATH. Technology Report: Vial Bundling Clip. An overview report on vial bundling clips to prevent vaccine reconstitution errors.

12.06.2019 Page 18 of 18